Literature DB >> 30953096

Locally recurrent rectal cancer: what the radiologist should know.

Dhakshinamoorthy Ganeshan1, Stephanie Nougaret2,3, Elena Korngold4, Gaiane M Rauch1, Courtney C Moreno5.   

Abstract

Despite advances in surgical techniques and chemoradiation therapy, recurrent rectal cancer remains a cause of morbidity and mortality. After successful treatment of rectal cancer, patients are typically enrolled in a surveillance strategy that includes imaging as studies have shown improved prognosis when recurrent rectal cancer is detected during imaging surveillance versus based on development of symptoms. Additionally, patients who experience a complete clinical response with chemoradiation therapy may elect to enroll in a "watch-and-wait" strategy that includes imaging surveillance rather than surgical resection. Factors that increase the likelihood of recurrence, patterns of recurrence, and the imaging appearances of recurrent rectal cancer are reviewed with a focus on CT, PET CT, and MR imaging.

Entities:  

Keywords:  Magnetic resonance imaging; Rectal cancer; Recurrent rectal cancer

Year:  2019        PMID: 30953096     DOI: 10.1007/s00261-019-02003-5

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  3 in total

Review 1.  Review of Radiomics- and Dosiomics-based Predicting Models for Rectal Cancer.

Authors:  Yun Qin; Li-Hua Zhu; Wei Zhao; Jun-Jie Wang; Hao Wang
Journal:  Front Oncol       Date:  2022-08-09       Impact factor: 5.738

2.  Radiomic signature of the FOWARC trial predicts pathological response to neoadjuvant treatment in rectal cancer.

Authors:  Zhuokai Zhuang; Zongchao Liu; Juan Li; Xiaolin Wang; Peiyi Xie; Fei Xiong; Jiancong Hu; Xiaochun Meng; Meijin Huang; Yanhong Deng; Ping Lan; Huichuan Yu; Yanxin Luo
Journal:  J Transl Med       Date:  2021-06-10       Impact factor: 5.531

Review 3.  Surgical treatment of locally recurrent rectal cancer: a narrative review.

Authors:  Zhaoya Gao; Jin Gu
Journal:  Ann Transl Med       Date:  2021-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.